We describe a liquid-chromatographic procedure for determination of cimetidine, its hydroxymethyl-, sulfoxide-, and guanyl urea metabolites, and creatinine in patients' serum and urine. SKF 92374 is used as the internal standard. Protein in 0.5 mL of serum or diluted urine is precipitated with 2 mL of acetonitrile, the organic and aqueous phases are separated by adding 0.3-0.5 g of anhydrous K2HPO4. The organic phase is evaporated, and 0.5 mL of 50 mmol/L HCI is added. This solution is washed with 3 mL of water-saturated isoamyl alcohol, the aqueous phase is extracted with 3 mL of methylene chloride and enough K2HP04 to saturate the solution. The methylene chloride is evaporated, the residue reconstituted with 100 zL of mobile phase, and a 25-giL aliquot injected onto the chromatographic column (Dupont Sil). The mobile phase is acetonitrile/methanol/water/ammonium hydroxide (1000/50/50/2, by vol). The column effluent is monitored at 228 nm. Lower limits of detection ranged from 0.05 mg/L for cimetidine to 0.2 mg/L for guanyl urea. We determined cimetidine and its principal metabolites in the serum of a patient receiving cimetidine for the treatment of Zollinger-Ellison syndrome, and have assessed use of the assay in a clinical setting.
. Adverse effects with this compound appear uncommon, but more side effects are being reported as utilization of the drug increases: mental confusion (5), cardiovascular problems (6) , anti-androgenic properties (7, 8) , and possibly blood dyscrasias such as leukopenia (9) and thrombocytopenia (10) . Because some of these effects may be dose related, clinical monitoring of cimetidine and its metabolites may be necessary to optimize therapy and minimize adverse effects.
Several assays have been developed for determination of cimetidine (11, 12) or its principal metabolite, cimetidine sulfoxide (13) . Because recovery of the drug is incomplete, these procedures have limited sensitivity and require relatively large sample volumes for analysis. Also, none of them quantitates all the known metabolites of cimetidine. The clinical role of these metabolites in efficacy or toxicity has not been evaluated, chiefly because of the lack of adequate analytical procedure.
graphic procedure that combines high sensitivity with reproducible extraction.
The assay allows quantitation of cimetidine, cimetidine sulfoxide, and its hydroxymethyl and guanyl urea derivatives.
The procedure has the additional advantage of measuring serum creatinine.
Materials and Methods

Reagents.
Cimetidine The phosphate salt effects separation of the acetonitrile (upper) phase from the salt-containing aqueous phase. Transfer 1.8 mL of the organic phase to a tapered glass centrifuge tube and evaporate it under a stream of nitrogen at 40-50 #{176}C. Reconstitute the residue with 0.5 mL of 50 mmol/L hydrochloric acid, then add 3.0 mL of water-saturated isoamyl alcohol (Fisher), vortex-mix for 60s, centrifuge, and aspirate and discard the organic (upper) phase. Transfer a 400-1jL aliquot of the aqueous phase to a second polypropylene tube containing 3.0 mL of methylene chloride. Again add K2HPO4 to saturate the aqueous phase and extract the sample for 1 h (we used a Fisher Roto-Rack).
Centrifuge the samples, transfer 2.9 mL of the methylene chloride phase to a disposable glass test tube, and evaporate it. Reconstitute the residue in 100 L of the mobile phase and inject 25 tL onto the column. Typically, one person can extract 25 samples in 4 h. By experimentation we determined that the extracted materials are stable for a minimum of 24 h in the final methylene chloride phase if stored at 5-10 #{176}C. Accordingly, one may perform the extraction procedure the day before chromatographic analysis.
Analytical recovery and precision. Recovery experiments
were performed by adding cimetidine, its metabolites, and creatinine to both an albumin solution and a solution of mobile phase containing the internal standard. The serum samples were then extracted according to our procedure except that the internal standard was added just before injection according to the external standard method. Percentage recovery was determined by comparing the peak height ratios for the extracted samples with those obtained from direct injection of the mobile-phase standard. Recovery studies were carried out at two concentrations, with five replicate determinations at each concentration.
We assayed a serum sample of known concentration five times to determine the within-day variation. A second serum sample was repeatedly assayed five separate times during 14 days, to assess between-day variation.
Patients' samples.
A patient hospitalized with ZollingerEllison syndrome, who was unresponsive to oral cimetidine, received a 1200-mg intravenous infusion of cimetidine. Blood was sampled at various time intervals up to 6 h post-infusion were assayed by our procedure.
Quantitation.
Serum albumin stock solutions of known concentration were simultaneously analyzed with patients'
samples. All compounds were quantitated as peak height ratio (drug to internal standard) vs concentration. The serum concentration/time profiles were evaluated by nonlinear least squares regression analysis (14) . Figure 1 shows the chromatogram obtained on subjecting 0.5 mL of blank human serum to the analytical procedure. The peak eluting at 13.2 mm is the endogenous creatinine present, which corresponds to a serum creatinine concentration of 9 mg/L with our assay. No additional peaks were seen in the chromatogram that could interfere with determination of any of the compounds.
Results
The use of human serum in preparation of standards would be inappropriate because of the presence of endogenous creatinine, therefore were prepared our standards in a 40 g/L solution of human serum albumin. This solution had recovery and extractability characteristics similar to those of human serum. Figure 2 shows such a chromatogram.
Cimetidine, its metabolites and the internal standard are well resolved. Table   1 lists the retention times of these compounds. A typical chromatogram of serum from a hospitalized patient with renal disease who was receiving cimetidine is shown in Figure 3 . The sample was obtained 2 h after a 300-mg intravenous dose of cimetidine. As can be seen, no additional peaks are present even though the patient was receiving concomitant therapy with other drugs. Figure 4 shows the standard curves for creatinine, cimetidine, and its metabolites.
All curves were linear over the concentration range of interest; samples with concentrations outside this range were rediluted before re-extraction. Creatinine concentrations monitored at 254 nm are graphed as mg/dL its relatively high concentrations in serum. To eliminate this problem we monitored the effluent for creatinine at 254 nm with a second detector. In those instances where creatinine concentrations were less than 1 mg/L, we used 228 nm. Table 2 summarizes the results of recovery experiments performed for both high and low concentrations. Recoveries were excellent and in some instances approached quantitative extraction.
The results of recovery reproducibility experiments are also shown in Table 2 .
The results of between-day and within-day variations studies are presented in Table 3 . Reproducibility was excellent, both within-and between-day, for all compounds.
Because clinical monitoring is the usual goal of most assays, we checked for possible drug or serum interferences with determination of these compounds. The assay was evaluated in hospitalized individuals who were receiving cimetidine for various diseases. Concomitant drug therapy was not controlled Table 2 while the sulfoxide and hydroxymethyl had half lives of 2.8 and 3.2 h, respectively. In this patient, we did not detect the guanyl urea metabolite.
Discussion
Cimetidine, its sulfoxide, hydroxymethyl, and guanyl urea derivatives, and creatinine are structurally similar (Table 1 ). All are highly water soluble, making difficult the quantitative pH partition-based extraction into a hydrophobic organic solvent. This difficulty is evidenced by the low recovery for these compounds typically reported by those procedures that incorporate a classic organic extraction procedure (11, 13) . Our procedure involves similar chromatographic conditions to previous methods, but circumvents the extractability problem by employing organic solvents of high polarity, and using an inorganic phosphate salt to increase extractability. Although several salts were evaluated, we preferred dibasic potassium phosphate because of its high water-affinity characteristics and basic pKa. Table 1 summarizes the results we obtained with this procedure. The sensitivity limits presented are those obtained by using 0.5 mL of human serum and a signal/noise ratio of 3. These limits are more than adequate, and samples smaller than 500 1zL are routinely used for clinical monitoring of cimetidine.
In those instances where additional sensitivity is required, either due to excessively low serum concentrations or a too-small sample, 50 1zL of the final reconstituted sample can be injected, thus doubling the lower limit of detection.
Recovery studies were performed at both high and low concentrations to assess any differences in the extractability of these compounds. Cimetidine and its hydroxymethyl and sulfoxide derivatives all showed almost complete recoveries at both concentrations. Recovery of guanyl urea cimetidine and creatinine were somewhat lower, owing to their limited extractability in the methylene chloride phase; however, these recovery values are adequate for routine determinations. No interconversion during analysis was seen for cimetidine sulfoxide, hydroxymethyl cimetidine, or guanyl urea cimetidine, but cimetidine is converted to its sulfoxide metabolite during the methylene chloride/K2HPO4-HC1 extraction to the extent of 1.3% ± 0.9% (n = 12).
This procedure has several distinct advantages over previous methods. The excellent recoveries allow for a high degree of sensitivity, thus minimal sample is required for analysis.
Inter-assay variation is small. One clinical advantage of our procedure is the capacity to monitor both the hepatic and renal pathways of cimetidine elimination. The assay also measures serum and urine creatinine, thus allowing for an estimation of renal function. Quantitation of cimetidine's principal metabolites may provide a useful estimate of liver function.
Both pieces of information can aid in evaluating a patient's overall clinical situation.
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